XACIG(SH:600596)2025-01-24 10:05Financial Performance Forecast - The company expects a net profit attributable to shareholders for 2024 to be between 30 million and 60 million yuan, a decrease of 57.21% to 78.60% compared to the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -140 million and -110 million yuan, a decline of 346.27% to 413.44% year-on-year[4]. - The previous year's net profit attributable to shareholders was 140.22 million yuan, with a net profit of 44.67 million yuan after deducting non-recurring gains and losses[5]. - The total profit for the previous year was 309.16 million yuan, with earnings per share of 0.1206 yuan[5]. Factors Affecting Performance - The significant decrease in performance is primarily due to the continuous decline in product prices influenced by macroeconomic conditions and market supply-demand changes[6]. - The company's main products, glyphosate and organosilicon, have experienced price declines compared to the previous year, impacting overall performance[6]. - The associated company, Beijing Yingtai Jiahe Biotechnology Co., Ltd., is expected to incur a loss of 500 million to 600 million yuan, significantly affecting the company's investment income[6]. Forecast Accuracy and Disclosure - The company assures that there are no significant uncertainties affecting the accuracy of this performance forecast[7]. - The forecast data is preliminary and subject to change, with the final audited financial data to be disclosed in the 2024 annual report[8].